Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Chih-Yung Yang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

C. Yang1, C. Lin2, J. Jiang3

Author affiliations

  • 1 Department Of Education And Research, Taipei City Hospital, 106 - Taipei/TW
  • 2 Institute Of Microbiology And Immunology, National Yang-Ming University, 112 - Taipei/TW
  • 3 Department Of Surgery, Taipei Veterans General Hospital, 112 - Taipei/TW
More

Resources

Abstract 1235

Background

It is difficult to predict relapse in patients with stage II colorectral cancer (CRC). In recent years, circulating cell-free DNA (cfDNA) from peripheral blood represents a promising biomarker for detection, monitoring and survival prediction of metastatic colorectal cancer (CRC). However, its prognostic significance in patients with stage II CRC remains uncertain.

Methods

In this study, the blood samples were drawn from mesenteric vein (MV) and peripherial vein (PV). MV and PV cfDNA level was quantified by real-time quantitative PCR of ALU repeats. The cfDNA from MV and PV was quantified and the correlation among the cfDNA concentration, clinicopathological features and multivariate survival was analyzed in CRC patients.

Results

Our results showed the MV cfDNA concentrations were lower in early stage than late stage CRC. We also found that MV cfDNA level was positively correlated with tumor size. Stage II CRC patients with higher cfDNA concentrations have better prognosis than those with lower cfDNA concentrations.

Conclusions

These results indicated that MV cfDNA concentration has prognostic value in stage II CRC patients and may act as an additional biomarker in stage II CRC patients for receiving chemotherapy criteria.

Clinical trial identification

Legal entity responsible for the study

Chih-Yung Yang.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings